Peer-reviewed veterinary case report
High fecal S100A12 levels predict poor treatment response in dogs
By Heilmann, Romy M et al.Ā·Published in Veterinary journal (London, England : 1997)Ā·2016Ā·Department of Small Animal Clinical Sciences, United StatesĀ·View original on PubMed ā
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research ā every detail traces back to the citation above. How we work ā
Original publication title: Fecal S100A12 concentration predicts a lack of response to treatment in dogs affected with chronic enteropathy.
- Species:
- dog
Plain-English summary
A group of dogs with chronic gastrointestinal issues, known as chronic enteropathy, were studied to see if a specific protein in their stool (S100A12) could predict how well they would respond to treatment. The dogs were divided into categories based on their condition and treatment response. It was found that dogs with inflammatory bowel disease (IBD) who did not improve had much higher levels of this protein compared to those who did respond to treatment. This suggests that measuring fecal S100A12 could help veterinarians determine which dogs might not respond well to treatment, potentially guiding better care strategies.
People also search for: dog chronic diarrhea treatment Ā· dog inflammatory bowel disease symptoms Ā· fecal S100A12 test for dogs
Abstract
S100A12 is a potential biomarker of gastrointestinal inflammation in dogs and fecal S100A12 concentrations are correlated with disease severity and outcome. The aim of the present study was to investigate whether there was any association between pre-treatment fecal S100A12 concentrations in dogs affected with chronic enteropathy (CE) and the response to treatment. Dogs affected with CE were recruited into the study and were classified as antibiotic-responsive diarrhea (ARD; n = 9), food-responsive diarrhea (FRD; n = 30) or idiopathic inflammatory bowel disease (IBD; n = 25). They were also grouped based on their response to treatment as complete remission (n = 35), partial response (n = 25) or no response (n = 4). Fecal S100A12 concentrations, measured by ELISA, were elevated in dogs affected with IBD compared with those from dogs affected with FRD (P = 0.010) or ARD (P = 0.025). Dogs with IBD that did not respond to treatment (n = 4) had significantly greater fecal S100A12 concentrations than dogs in complete remission (P = 0.009). Measurement of fecal S100A12 at the time of diagnosis discriminated between dogs with IBD that were refractory to therapy (≥2700 ng/g fecal S100A12) from those with at least a partial response (<2700 ng/g fecal S100A12), with a sensitivity of 100% and a specificity of 76%. These preliminary results suggest that testing of fecal S100A12 may be useful for predicting the lack of response to treatment in dogs affected with CE. The utility of serial fecal S100A12 measurements for monitoring dogs undergoing treatment for CE warrants further investigation.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases āOriginal publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27017054/